*Americans now have expanded access to sexual health screening and treatment following recent federal approvals of at-home testing options and novel medications.
According to KNOE 8 News, the Food and Drug Administration greenlit the first home-based test capable of identifying three prevalent infections in women, gonorrhea, chlamydia, and trichomoniasis, alongside a kit for detecting the virus linked to cervical cancer.
The agency also authorized two different gonorrhea drugs, representing the first fresh treatment alternatives for the condition in decades. These developments arrive as sexually transmitted infection rates reached concerning levels before and throughout the COVID-19 pandemic, which disrupted nationwide screening programs, education initiatives, and treatment access.
The pandemic period accelerated testing innovation, with technology initially developed for over-the-counter coronavirus tests now adapted for syphilis and other sexually transmitted infection kits. The FDA had previously restricted such testing primarily to healthcare professionals.
Scroll to continue reading
Dr. Ina Park, a sexual health specialist at the University of California, San Francisco, highlighted the benefits of increased accessibility. “Sexual health can be stigmatized and people can be hesitant about testing,” Park said. “Now we have a lot of options for patients who may be wary of going into a provider’s office.”
Visby Medical introduced its three-infection test for women following March FDA approval. The $150 product includes a vaginal swab and compact testing device, with results viewable through a mobile application after users photograph the device. A telehealth consultation with medical providers who can authorize antibiotics or other treatments accompanies the test.
Dr. Gary Schoolnik, Visby’s chief medical officer, notes the streamlined process can deliver prescriptions within six hours compared to multiple days under conventional testing procedures. “Many patients are very hard to track down and a lot of them, if they have a positive test result, are never treated and are lost to follow-up,” said Schoolnik, who serves as professor emeritus at Stanford Medical School.
Study data supporting FDA authorization demonstrated the Visby test correctly identified the three infections with accuracy rates approximating 98% or higher, matching performance levels of hospital and clinic-based testing.
MORE NEWS ON EURWEB.COM: GA Mother Demands Answers After Urgent Care Wrongly Reports 5-Year-Old Had Multiple STDs
Sign up for our Free daily newsletter HERE.
